Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$4.28 - $6.57 $77,981 - $119,705
18,220 New
18,220 $79,000
Q2 2022

Aug 12, 2022

SELL
$9.31 - $11.84 $209,856 - $266,885
-22,541 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$10.84 - $16.55 $131,597 - $200,917
-12,140 Reduced 35.0%
22,541 $255,000
Q4 2021

Feb 14, 2022

BUY
$15.69 - $21.14 $544,144 - $733,156
34,681 New
34,681 $544,000
Q2 2021

Aug 13, 2021

SELL
$15.71 - $21.51 $413,063 - $565,562
-26,293 Closed
0 $0
Q1 2021

May 14, 2021

BUY
$13.42 - $20.28 $352,852 - $533,222
26,293 New
26,293 $395,000
Q2 2020

Aug 14, 2020

SELL
$9.66 - $12.02 $109,032 - $135,669
-11,287 Closed
0 $0
Q1 2020

May 13, 2020

SELL
$7.5 - $16.8 $44,295 - $99,220
-5,906 Reduced 34.35%
11,287 $117,000
Q4 2019

Feb 14, 2020

BUY
$12.38 - $17.47 $47,947 - $67,661
3,873 Added 29.08%
17,193 $282,000
Q3 2019

Nov 14, 2019

BUY
$12.27 - $15.79 $163,436 - $210,322
13,320 New
13,320 $177,000
Q2 2019

Aug 14, 2019

SELL
$13.37 - $18.85 $193,290 - $272,514
-14,457 Closed
0 $0
Q1 2019

May 13, 2019

BUY
$17.59 - $31.05 $254,298 - $448,889
14,457 New
14,457 $266,000
Q2 2018

Aug 14, 2018

SELL
$13.95 - $19.15 $199,833 - $274,323
-14,325 Closed
0 $0
Q1 2018

Jun 14, 2018

SELL
$14.05 - $20.2 $120,773 - $173,639
-8,596 Reduced 37.5%
14,325 $242,000
Q1 2018

May 14, 2018

BUY
$14.05 - $20.2 $322,040 - $463,004
22,921 New
22,921 $387,000
Q4 2017

Feb 09, 2018

SELL
$12.85 - $18.1 $199,444 - $280,930
-15,521 Closed
0 $0
Q3 2017

Nov 08, 2017

SELL
$15.4 - $18.85 $76,830 - $94,042
-4,989 Reduced 24.32%
15,521 $278,000
Q2 2017

Aug 17, 2017

BUY
N/A
20,510
20,510 $335,000

Others Institutions Holding VNDA

About Vanda Pharmaceuticals Inc.


  • Ticker VNDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,561,500
  • Market Cap $249M
  • Description
  • Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...
More about VNDA
Track This Portfolio

Track Dynamic Technology Lab Private LTD Portfolio

Follow Dynamic Technology Lab Private LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dynamic Technology Lab Private LTD, based on Form 13F filings with the SEC.

News

Stay updated on Dynamic Technology Lab Private LTD with notifications on news.